FTZ can also upregulate the expression levels of P-AMPK and BCL-2 while downregulating BAX, thereby improving steatosis and hepatocyte apoptosis to attenuate NASH [122]. This evidence concerns the gene BAX and metabolic dysfunction-associated steatohepatitis.